Sclerosing cholangitis
MONDO:0018646A chronic, autoimmune inflammatory liver disorder characterized by narrowing and scarring of the lumen of the bile ducts. It is often seen in patients with ulcerative colitis. Signs and symptoms include jaundice, fatigue, and malabsorption. It may lead to cirrhosis and liver failure.
Also known as: Primary sclerosing cholangitis, primary sclerosing cholangitis (PSC), sclerosing cholangitis, sclerosing cholangitis (disease)
73 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New drug A3907 tested for rare liver disease, study halted early
Disease control TerminatedThis study tested a drug called A3907 in 18 adults with Primary Sclerosing Cholangitis (PSC), a rare liver disease. The goal was to check if the drug is safe and how the body processes it. The study was stopped early, so results are limited.
Phase: PHASE2 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Antibiotic vancomycin tested as PSC treatment – trial stopped early
Disease control TerminatedThis study tested whether the antibiotic vancomycin, taken by mouth, is safe and effective for adults with primary sclerosing cholangitis (PSC), a rare liver disease. About 102 participants were randomly assigned to receive vancomycin or a placebo. The main goal was to see if van…
Phase: PHASE2, PHASE3 • Sponsor: Elizabeth Carey • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC